The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review
Open accessAbstract
BACKGROUND: Schizophrenia is a highly heterogeneous disorder, and around a third of patients are treatment-resistant. The only evidence-based treatment for these patients is clozapine, an atypical antipsychotic with relatively weak dopamine antagonism. It is plausible that varying degrees of response to antipsychotics reflect categorically distinct illness subtypes, which would have significant implications for research and clinical practice. If these subtypes could be distinguished at illness onset, this could represent a first step towards personalised medicine in psychiatry. This systematic review investigates whether current evidence supports conceptualising treatment-resistant and treatment-responsive schizophrenoa as categorically distinct subtypes. METHOD: A systematic literature search was conducted, using PubMed, EMBASE, PsycInfo, CINAHL and OpenGrey databases, to identify all studies which compared treatment-resistant schizophrenia (defined as either a lack of response to two antipsychotic trials or clozapine prescription) to treatment-responsive schizophrenia (defined as known response to non-clozapine antipsychotics). RESULTS: Nineteen studies of moderate quality met inclusion criteria. The most robust findings indicate that treatment-resistant patients show glutamatergic abnormalities, a lack of dopaminergic abnormalities, and significant decreases in grey matter compared to treatment-responsive patients. Treatment-resistant patients were also reported to have higher familial loading; however, no individual gene-association study reported their findings surviving correction for multiple comparisons. CONCLUSIONS: Tentative evidence supports conceptualising treatment-resistant schizophrenia as a categorically different illness subtype to treatment-responsive schizophrenia. However, research is limited and confirmation will require replication and rigorously controlled studies with large sample sizes and prospective study designs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Age of onset of mental disorders: a review of recent literature
Kessler, R. C., Amminger, G. P., Aguilar-Gaxiola, S., Alonso, J., Lee, S., & ??st??n, T. B. (2007) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32816ebc8c · Cited by 3,457
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia
Shepherd, A. M., Laurens, K. R., Matheson, S. L., Carr, V. J., & Green, M. J. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.12.015 · Cited by 412
The social and economic burden of treatment-resistant schizophrenia: a systematic literature review
Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32836508e6 · Cited by 392
The involvement of Reelin in neurodevelopmental disorders
Folsom, T. D., & Fatemi, S. H. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.08.015 · Cited by 275
Clinical predictors of therapeutic response to antipsychotics in schizophrenia
Carbon, M., & Correll, C. U. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/mcarbon · Cited by 257
Clozapine: a review of clinical practice guidelines and prescribing trends
Warnez, S., & Alessi-Severini, S. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-102 · Cited by 234
López-Gil, X., Babot, Z., Amargós-Bosch, M., Suñol, C., Artigas, F., & Adell, A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301356 · Cited by 183 · cited 1×
“One possible mechanism underlying the efficacy of clozapine in treatment-resistant illness may relate to its’ ability to attenuate glutamate release, as demonstrated in several rat studies [54, 55].”
BackgroundPredictors of treatment resistance in patients with schizophrenia: a population-based cohort study
Wimberley, T., Støvring, H., Sørensen, H. J., Horsdal, H. T., MacCabe, J. H., & Gasse, C. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00575-1 · Cited by 153
Self-citation
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Self-citationTreatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives
Nucifora, F. C., Woznica, E., Lee, B. J., Cascella, N., & Sawa, A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.016 · Cited by 304
Saleh, Y., Jarratt-Barnham, I., Petitet, P., Fernandez-Egea, E., Manohar, S. G., & Husain, M. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02232-7 · Cited by 45
Krivoy, A., Hochman, E., Sendt, K.-V., Hollander, S., Vilner, Y., Selakovic, M., Weizman, A., & Taler, M. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.05.040 · Cited by 33
Understanding the experience of “burnout” in first-episode psychosis carers
Onwumere, J., Sirykaite, S., Schulz, J., Man, E., James, G., Afsharzadegan, R., Khan, S., Harvey, R., Souray, J., & Raune, D. (2018) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2018.02.003 · Cited by 30
Metadata
- Authors
- Gillespie, A. L., Samanaite, R., Mill, J., Egerton, A., & MacCabe, J. H.
- Venue
- BMC Psychiatry
- Published
- 2017-01-13
- Volume
- 17
- Issue
- 1
- Pages
- 12-12
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W2578041951
- Cited by
- 240
- References
- 12
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. https://app.cochat.ai/papers/10.1186/s12888-016-1177-y
- The paper
- Gillespie, A. L., Samanaite, R., Mill, J., Egerton, A., & MacCabe, J. H. (2017). Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. BMC Psychiatry. https://doi.org/10.1186/s12888-016-1177-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.